SCHEMBL4130347

SCHEMBL4130347

Cc1cc(I)ccc1N=C=S

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
LMNA P02545 1/20 0.36
ABCB11 O95342 1/20 0.33
NR3C1 P04150 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ADRA2C P18825 1/20 0.33
MAOA P21397 1/20 0.33
DRD1 P21728 1/20 0.33
SLC6A4 P31645 1/20 0.33
HTR2B P41595 1/20 0.33
CCR2 P41597 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
APLNR P35414 1/20 0.33
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30421135 0.79 NPC1 (0.46) ALDH1A1LMNAABCB11NR3C1CYP1A2
SCHEMBL1993331 0.79 ALDH1A1 (0.41) ALDH1A1LMNAABCB11NR3C1CYP1A2
SCHEMBL945304 0.79 NPC1 (0.46) ALDH1A1LMNAABCB11NR3C1CYP1A2
SCHEMBL16707534 0.78 P2RY6 (0.42) ALDH1A1LMNAABCB11NR3C1CYP1A2
SCHEMBL27230128 0.76 NPC1 (0.45) ALDH1A1LMNACYP1A2CYP3A4ADRA2A
SCHEMBL27207547 0.76 NPC1 (0.45) ALDH1A1LMNACYP1A2CYP3A4ADRA2A
SCHEMBL1457266 0.76 ALDH1A1 (0.42) ALDH1A1LMNAABCB11NR3C1CYP1A2
SCHEMBL3972524 0.76 IDO1 (0.34) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL990169 0.76 ABCB11 (0.33) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL893836 0.76 ALDH1A1 (0.36) ALDH1A1LMNAABCB11NR3C1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604051-B2 Thieno-pyridine derivatives as MEK inhibitors UCB PHARMA S.A. (BE) 2013-12-10 US disclosed
US-20130150573-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2013-06-13 US disclosed
US-8394822-B2 Thieno-pyridine derivatives as MEK inhibitors UCB PHARMA, S.A. (BE) 2013-03-12 US disclosed
US-20120329774-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2012-12-27 US disclosed
US-8283359-B2 Thieno-pyridine derivatives as MEK inhibitors UCB PHARMA S.A. (BE) 2012-10-09 US disclosed
US-20090149437-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 US disclosed
EP-1981892-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB Pharma, S.A. (BE) 2008-10-22 EP disclosed
WO-2007088345-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2007-08-09 WO disclosed
US-5310724-A Pre- and postemergence; plant growth regulators FMC CORPORATION (US) 1994-05-10 US disclosed
US-5108486-A Herbicides KANAGAWA CHEMICAL LABORATORY, LTD. (JP) 1992-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329774-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS MAP3K6, MAPK1, MAP3K20 ALDH1A1 2577/4885LMNA 4288/4885ABCB11 4256/4885
US-20090149437-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS MAP3K6, MAPK1, MAP3K20 ALDH1A1 2577/4885LMNA 4288/4885ABCB11 4256/4885
US-20130150573-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS MAP2K2, MAPK1, MAP3K6 ALDH1A1 2344/4885LMNA 4035/4885ABCB11 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.